Streetbeat News

Price Targets

BAC

Phillip Securities has upgraded Bank of America (NYSE:BAC) from Neutral to Accumulate, setting a price target of $44.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:40 pm

CTO

Jones Trading analyst Jason Weaver maintains a Buy rating on CTO Realty Growth and raises the price target from $20.5 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:40 pm

LAC

Scotiabank analyst Ben Isaacson has maintained a Sector Perform rating on Lithium Americas (NYSE:LAC) but has lowered the price target from $3 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:36 pm

ORCL

JMP Securities has maintained a Market Outperform rating on Oracle and raised its price target from $175 to $205, indicating confidence in Oracle's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:35 pm

BX

NFLX

NVDA

UBER

Top Wall Street analysts have updated their price targets for several major companies. Notable changes include NVIDIA's target raised by B of A Securities, Blackstone's by TD Cowen, and Netflix's by Bernstein. These updates reflect varying levels of confidence in the companies' future performance.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 3:34 pm

VZ

Scotiabank analyst Maher Yaghi maintains a Sector Perform rating on Verizon Communications and raises the price target from $46.5 to $47.25.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:33 pm

XMTR

JMP Securities analyst Nicholas Jones maintains a Market Outperform rating on Xometry (NASDAQ:XMTR) and raises the price target from $27 to $32.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:32 pm

CMCSA

Scotiabank analyst Maher Yaghi maintains a Sector Perform rating on Comcast and raises the price target from $47.25 to $47.75.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:32 pm

AURA

Scotiabank analyst George Farmer has maintained a Sector Outperform rating on Aura Biosciences and raised the price target from $20 to $23.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:26 pm

OTLK

BTIG analyst Julian Harrison has reiterated a Buy rating on Outlook Therapeutics (NASDAQ:OTLK) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:25 pm